Tofacitinib May Reduce Interstitial Lung Disease Risk in RA
MedPage Today
Mar 23, 2023
Tofacitinib (Xeljanz) in patients with rheumatoid arthritis (RA) stood out among several other biologic and targeted synthetic disease-modifying antirheumatic drugs (sDMARDs) when it came to the incidence of interstitial lung disease (ILD), a retrospective cohort study showed.
Read Article